Search results
Results from the WOW.Com Content Network
A parasympathomimetic drug, sometimes called a cholinomimetic drug [1] or cholinergic receptor stimulating agent, [2] is a substance that stimulates the parasympathetic nervous system (PSNS).
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood.With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Like insulin, GLP-1 agonists can cause or exacerbate retinopathy, but this is believed to be caused indirectly by a rapid drop in glucose rather than a direct effect. [8] Some patients develop anti-drug antibodies , which are more common with exenatide (the antibodies were detectable in a third or more of patients) than other GLP-1 agonists and ...
Insulin detemir works by increasing the amount of glucose absorbed by tissues and reducing the amount of glucose produced by the liver. [75] Insulin detemir was approved for medical use in the European Union in June 2004 and in the United States in June 2005. [77] [75] [78] It is listed on the World Health Organization's List of Essential ...
It was found that Acarbose appeared to reduce incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose compare to diet and exercise, metformin, placebo, no intervention improved all-cause mortality, reducer or increased risk of cardiovascular mortality, serious or non-serious adverse ...
Pramlintide has been approved on 3/16/2005 by the FDA, for use by type 1 and type 2 diabetic patients who use insulin. [6] (subscription required) Pramlintide allows patients to use less insulin, lowers average blood sugar levels, and substantially reduces what otherwise would be a large unhealthy rise in blood sugar that occurs in diabetics right after eating.